Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s

Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s

Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.

Frequently Asked Questions

What is "Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s" about?

Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.

When was "Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s" published?

It was published on October 2, 2026 on Semasocial.

Who wrote "Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s"?

It was written by CNBC on Semasocial.

Comment